肥胖成人中精氨酸加压素动态与食物摄入及8周鼻内催产素治疗的关系
本研究基于一项8周随机临床试验的横断面和纵向数据,纳入63名肥胖成人,其中61人随机接受8周鼻内催产素(24 IU,每日4次)或安慰剂。结果显示,进食后60分钟精氨酸加压素水平较空腹下降,而8周鼻内催产素治疗与安慰剂相比未显著改变精氨酸加压素水平。
要点
- 肥胖成人进食后60分钟精氨酸加压素水平较空腹下降。
- 8周鼻内催产素治疗与安慰剂相比未显著改变精氨酸加压素水平。
- 体重指数和性别对精氨酸加压素水平无显著影响。
核心结论
- 肥胖成人进食后精氨酸加压素水平下降,提示精氨酸加压素信号可能受损,并可能与肥胖病理生理相关。
- 长期鼻内催产素给药未改变精氨酸加压素水平,支持基于催产素的治疗安全性。
研究设计与样本
- 研究采用横断面和纵向数据,来自一项在三级学术中心开展的8周随机临床试验。
- 共纳入63名肥胖成人(女性占56%,年龄33.7±6.3岁),其中61人被1:1随机分配至8周鼻内催产素(24 IU,每日4次)组或安慰剂组。
- 干预包括标准化餐食和鼻内催产素与安慰剂的比较。
- 主要结局指标为基线及开始催产素或安慰剂后第4、6、8周标准化餐前及餐后30、60、120分钟的精氨酸加压素水平。
主要发现
- 进食后60分钟精氨酸加压素水平(校正均值±标准误=68.55±9.64 pg/mL)较空腹(80.99±11.22 pg/mL)下降,P=0.022。
- 8周鼻内催产素治疗与安慰剂相比,精氨酸加压素水平无显著变化(P≥0.544)。
- 体重指数对精氨酸加压素水平无显著影响(P≥0.615),性别对精氨酸加压素水平无显著影响(P≥0.498)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Oxytocin (OXT) and arginine-vasopressin (AVP) are structurally similar hypothalamic-pituitary peptides with broad physiologic actions including regulation of caloric intake and metabolism. While OXT is under investigation as an antiobesity therapeutic, there are no data on endogenous AVP levels in relation to eating behavior in humans. Further, the effects of exogenous OXT on AVP dynamics, which could affect safety of treatment given AVP effects on water balance, are not well understood. OBJECTIVE: This work aimed to define secretory dynamics of circulating AVP around a standardized meal and in response to 8 weeks (W) intranasal (IN) OXT vs placebo in adults with obesity. METHODS: Cross-sectional and longitudinal data were used from an 8-W randomized clinical trial at a tertiary academic center. Participants included 63 adults with obesity (56% women, age 33.7 ± 6.3 years) of whom 61 were randomly assigned 1:1 to 8-W IN OXT (24 IU) 4 times daily or placebo. Intervention included a standardized meal, IN OXT vs placebo. Main outcome measure was AVP levels before and 30, 60, and 120 minutes after a standardized meal at baseline, and W4, 6, and 8 after starting OXT or placebo. RESULTS: In response to food intake, AVP levels decreased at 60 minutes (adjusted mean ± SE = 68.55 ± 9.64 pg/mL) compared to fasting (80.99 ± 11.22 pg/mL; P = .022). AVP levels did not significantly change over the course of 8-W IN OXT treatment vs placebo (P ≥ .544). There was no effect of body mass index (P ≥ .615) or sex (P ≥ .498) on AVP levels. CONCLUSION: AVP levels decreased after food intake in adults with obesity, indicating a potential disruption in AVP signaling and possibly underlying obesity pathophysiology. Chronic IN OXT administration did not alter AVP levels, supporting safety of OXT-based therapeutics.
引用
- Aulinas A, Galbiati F, Wronski ML, et al. Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With Obesity. J Clin Endocrinol Metab. 2025. PMID: 40314146. doi:10.1210/clinem/dgaf237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。